By Kailyn Rhone
Shares of MaxCyte jumped after the company raised its revenue-growth guidance and said it cut about 15% of its workforce.
The commercial cell-engineering company's stock was up 20% at $4.33 in afternoon trading Monday. For the year, shares are down 8%.
The Rockville, Md., company said Monday it expects full-year core business revenue to grow by 6% to 8% from 2023. In March, the company said it expected full-year core business revenue to be flat to up 5%.
MaxCyte continues to expect to end the year with $185 million in cash, cash equivalents and investments. It also expects revenue related to its strategic-platform-licence program to be around $6 million after the signing of six deals in the fiscal year.
The company said it cut 21 positions, reflecting about 15% of its personnel globally, to streamline operations. MaxCyte had 143 full-time employees as of Dec. 31, 2023. It expects to end the fiscal year with 116 employees.
With the workforce reduction, the company expects anticipated cost savings in 2025 of about $5.8 million.
Write to Kailyn Rhone at kailyn.rhone@wsj.com
(END) Dow Jones Newswires
December 09, 2024 13:55 ET (18:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。